NCT07869615 Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
| NCT ID | NCT07869615 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Military Hospital of Tunis |
| Condition | Total Knee Arthroplasty |
| Study Type | INTERVENTIONAL |
| Enrollment | 138 participants |
| Start Date | 2026-09-15 |
| Primary Completion | 2027-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 138 participants in total. It began in 2026-09-15 with a primary completion date of 2027-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1\. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total knee arthroplasty: rivaroxaban 10 mg once daily, apixaban 2.5 mg twice daily, and low-molecular-weight heparin (LMWH) once daily. The study will assess venous blood flow in the lower limbs using Doppler ultrasound and determine whether blood flow differs between the three treatment groups. Participants will be randomly assigned to one of the three treatment groups and followed for 28 days after surgery. Doppler ultrasound examinations will be performed at baseline and on Days 7, 15, 21, and 28. Additional assessments will include rehabilitation progress, postoperative bleeding, suspected venous thromboembolism, cardiovascular complications, and other postoperative complications. The study is being conducted at the Department of Anesthesiology, Principal Military Hospital of Instruction of Tunis.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older undergoing elective primary unilateral total knee arthroplasty. * Able to provide informed consent. Exclusion Criteria: * Allergy or contraindication to the study medications. * Requirement for long-term therapeutic anticoagulation. * Requirement for antiplatelet therapy. * Pregnancy or lactation. * Active cancer or cancer treatment. * Documented previous venous thromboembolism in the target limb. * Hypercoagulable state. * BMI \>40 kg/m². * Severe inflammatory disease. * Age \>80 years. * Inability to comply with follow-up. * Incomplete data.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07869615 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Total Knee Arthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07869615 currently recruiting?
Yes, NCT07869615 is actively recruiting participants. Contact the research team at haythem.elaskri@fmt.utm.tn for enrollment information.
Where is the NCT07869615 trial being conducted?
This trial is being conducted at Tunis, Tunisia.
Who is sponsoring the NCT07869615 clinical trial?
NCT07869615 is sponsored by Military Hospital of Tunis. The trial plans to enroll 138 participants.